JNJ

ACCE-researched
Johnson & Johnson Common Stock
Healthcare · Drug Manufacturers - General · NYSE · United States
$269.99-0.09%
Market cap $650.6BNext earnings 2026-10-13Updated Sep 20, 2026
FAIR VALUE · CONSENSUS
$269.99+0.0%
confidence-weighted across 4 of 6 models
Now $269.99
$269.99
$91.65$258.52
AvoidBronze54
Price vs fair value
62.0% above
-38.3% to fair value
ACCE score
66
out of 100
Analysts
46% buy
24 covering
P/E
31.4x
forward 21.1x
1-year return
+55.0%
Dividend yield
1.94%
Unlock the ACCE read
INVESTOR

Overview

⚠ Investor warnings · 2 flags
  • high
    Earnings collapsed 52.9%
    YoY earnings down 52.9% despite 9.9% revenue growth signals major one-time charges or structural cost issues masking operational deterioration.
  • moderate
    Revenue growth decelerating
    QoQ revenue declined 2.0%, suggesting the 9.9% YoY figure may not be sustained; momentum is fading near-term.
Reports in 21 days, last quarter beat by 0.0%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+55.0% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Mixed46% buy · 24 covering analysts
● Strong buy 7● Buy 4● Hold 13● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 50% of peers
low 21.0x31.4xhigh 117.5x
ROEbetter than 33% of peers
low 7%26%high 102%
Div yieldbetter than 17% of peers
low 0.6%1.9%high 4.0%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
ABBVAbbVie Inc. Common Stock$466.4B74.662.3%-20.912.6%-Compare
LLYEli Lilly and Company Common Stock$1027.7B38.8102.3%1.600.6%-Compare
MRKMerck & Company Inc. Common Stock (new)$362.4B117.57.0%0.942.3%-Compare
NVSNovartis AG Common Stock$266.8B21.230.3%0.733.4%-Compare
NOVN.SWNovartis$265.0B21.030.3%0.734.0%-Compare
AZN.LAstraZeneca$258.7B25.022.0%0.572.6%-Compare

Sector report card

Where JNJ ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 21 days, last quarter beat by 0.0%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+1.7%
1 month
-1.3%
3 months
+18.2%
6 months
+14.7%
YTD
+30.5%
1 year
+55.0%

SEC filings

40 filings
September 2026
Sep 10
Form 4Insider transactionPeriod 2026-09-08
Sep 10
Form 4Insider transactionPeriod 2026-09-08
Sep 10
Form 4Insider transactionPeriod 2026-09-08
37 more filings + AI summaries on Investor+.INVESTOR